Search
Now showing items 1-4 of 4
-
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
The Lancet, Elsevier, 2021, 22; 2, 198-211Compte-rendu et recension critique d'ouvragefulltext -
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
The Lancet, Elsevier, 01-2021, 397; 10272, 375-386Compte-rendu et recension critique d'ouvragefulltext -
Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma
Genome Medicine, BioMed Central, 14-07-2021, 13; 1, 113Compte-rendu et recension critique d'ouvragefulltext -
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
The Lancet Digital Health, Elsevier, 01-2021, 397; 10272, 375-386Compte-rendu et recension critique d'ouvragefulltext